These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 29162351)

  • 21. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.
    Zhan Y; Zhang G; Wang X; Qi Y; Bai S; Li D; Ma T; Sartor O; Flemington EK; Zhang H; Lee P; Dong Y
    Mol Cancer Res; 2017 Jan; 15(1):59-68. PubMed ID: 27671337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 23. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical decision-making with AR-V7.
    Thoma C
    Nat Rev Urol; 2019 Dec; 16(12):694. PubMed ID: 31690843
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Atala A
    J Urol; 2019 Nov; 202(5):869-870. PubMed ID: 31365309
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.
    Dirix L
    J Clin Oncol; 2019 Aug; 37(24):2180-2181. PubMed ID: 31265358
    [No Abstract]   [Full Text] [Related]  

  • 27. Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.
    Lamb AD; Lawrence MG; Sandhu S
    Eur Urol; 2017 Jun; 71(6):883-885. PubMed ID: 28089303
    [No Abstract]   [Full Text] [Related]  

  • 28. The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    Culig Z
    BJU Int; 2018 Aug; 122(2):169. PubMed ID: 30134059
    [No Abstract]   [Full Text] [Related]  

  • 29. AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.
    Sowalsky AG; Sharp A; Trostel SY; de Bono JS; Plymate SR
    Cancer Treat Res Commun; 2021; 28():100218. PubMed ID: 33516656
    [No Abstract]   [Full Text] [Related]  

  • 30. Ailanthone: a new potential drug for castration-resistant prostate cancer.
    Peng S; Yi Z; Liu M
    Chin J Cancer; 2017 Mar; 36(1):25. PubMed ID: 28257652
    [No Abstract]   [Full Text] [Related]  

  • 31. Living Longer and Better with Advanced Prostate Cancer.
    Mukherji D; Omlin A; Pezaro C
    Eur Urol; 2020 Sep; 78(3):358-359. PubMed ID: 32553618
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting DNA Repair in Prostate Cancer.
    Abida W; Sawyers CL
    J Clin Oncol; 2018 Apr; 36(10):1017-1019. PubMed ID: 29369701
    [No Abstract]   [Full Text] [Related]  

  • 33. Following the Narrow Path.
    Clarke NW
    Eur Urol; 2023 Jan; 83(1):27-28. PubMed ID: 36270833
    [No Abstract]   [Full Text] [Related]  

  • 34. UT-34: a promising new AR degrader.
    Stone L
    Nat Rev Urol; 2019 Nov; 16(11):640. PubMed ID: 31578494
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth.
    Atala A
    J Urol; 2019 Jul; 202(1):35-36. PubMed ID: 30925098
    [No Abstract]   [Full Text] [Related]  

  • 36. [Not Available].
    Rexer H; Hammerer P; Schostak M; König F
    Aktuelle Urol; 2018 Sep; 49(5):392-393. PubMed ID: 30184595
    [No Abstract]   [Full Text] [Related]  

  • 37. [Not Available].
    Rexer H; Gratzke C; Graefen M
    Aktuelle Urol; 2021 Feb; 52(1):26-27. PubMed ID: 33525025
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Markowski MC; Silberstein JL; Eshleman JR; Eisenberger MA; Luo J; Antonarakis ES
    JCO Precis Oncol; 2017; 2017():. PubMed ID: 29170762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV
    Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
    Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
    Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.